Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
